Orano Med
Dr. Evelyne Poli serves as Ingénieur méthodes de production at Orano Med since July 2023. Prior to this, Dr. Poli was involved in research and development at ICERAM from March 2016 to July 2023, leading the R&D department in chemistry. Dr. Poli's earlier experience includes a role as Ingénieur recherche en céramique at SPCTS-LCSN, focusing on the development of osteoinductive bioceramics and analytical methods for characterizing functionalized ceramics. Additional roles include project management and research at ENS Lyon, research engineering at ITQ Valencia-CSIC, and doctoral research at the Université de Poitiers, where Dr. Poli specialized in applied chemistry and green chemistry. Dr. Poli holds a Doctorat Européen in applied chemistry and degrees in organic chemistry from the Université de Poitiers and Limoges.
This person is not in any offices
Orano Med
1 followers
Based on an R&D program started in 2005, Orano Med has developed new processes for producing high-purity lead-212 (Pb-212), a rare radioactive isotope. Lead-212 is currently at the heart of promising projects in nuclear medicine to develop new treatments against cancer. The innovative approach, known as targeted alpha therapy (TAT), recognizes and destroys cancer cells while limiting the impact on nearby healthy cells. Macrocyclics, Inc., an Orano Med company, is the global leader in high performance chelating agent technology, offering a broad range of services and products. For more information please visit www.macrocyclics.com.